This page shows the latest Beovu news and features for those working in and with pharma, biotech and healthcare.
Novartis has claimed an EMA approval for VEGF inhibitor Beovu, its new drug for a leading cause of blindness that is competing with Bayer’s big-selling Eylea product. ... The company is also trumpeting Beovu’s less frequent dosing schedule compared
Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
Novartis recently claimed a US approval for a follow-up VEGF inhibitor Beovu (brolucizumab), which requires fewer injections into the eye, in an attempt to protect its AMD franchise ahead of
Head-to-head trial with rival Eylea could boost sales. The FDA has approved Novartis’ new VEGF inhibitor Beovu as a new treatment option for patients with the wet form of ... That compares to four to eight week dosing with Eylea, and every month with
Next gen eye treatment offers less frequent dosing
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...